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Access to drugs: the case of Abbott in Thailand
In March, 2007, Abbott Laboratories announced that 
it was withholding all new medicines from Thailand. 
The company’s position was put crudely: “Thailand 
has chosen to break patents on numerous medicines, 
ignoring the patent system. As such, we’ve elected not 
to introduce new medicines there.”
1 
Abbott was reacting to the Thai Ministry of Public 
Health’s announcement in January that it would issue 
compulsory licences for non-commercial use on a 
number of medicines. This move followed repeated 
attempts to negotiate aﬀ   ordable prices with several 
manufacturers,
2 including for Abbott’s lopinavir-ritonavir, 
an important antiretroviral medicine recommended as a 
second-line treatment for developing country settings.
3
Since late 2005, Médecins Sans Frontières and 
other groups have raised concern that Abbott has 
not prioritised the registration of the new version of 
lopinavir-ritonavir in less developed countries, and 
lacked clear plans for making the drug aﬀ  ordable. This 
new version, which was registered in the USA in October, 
2005, and in Europe in July, 2006, has several important 
advantages for tropical countries: it does not need to be 
refrigerated, has no food restrictions, and has a lower 
pill requirement.
In March, 2006, physicians and patient groups from 
24 countries wrote to Abbott requesting that the 
company immediately ﬁ  le for registration of the new 
lopinavir-ritonavir formulation in all countries where 
the old formulation was registered or pending (at the 
time this represented some 68 countries), as well as in 
all other developing countries.
4
Abbott responded that to be able to register in 
developing countries, they ﬁ  rst  needed  to  obtain 
a Certiﬁ   cate of Pharmaceutical Product (CPP) by 
registering in Europe. In fact, Abbott could have used 
the CPP that was provided upon approval in the USA 
in 2005. We have queried this issue several times but 
Abbott has simply reiterated their incorrect claim that a 
European CPP was required.
Abbott claimed that they would be registering their 
new tablet formulation of lopinavir-ritonavir “very 
soon” in Thailand, China, and Guatemala.
5 6 months 
after this promise was made, and more than a year since 
US Food and Drug Administration (FDA) approval was 
granted and the registration process could have begun, 
Abbott had still not submitted registration dossiers in 
China or Guatemala. 
In Thailand, registration was applied for in early 
September, 2006, but Abbott failed to include the CPP. 
On Sept 14, 2006, the Thai FDA informed Abbott of the 
missing documentation and proposed a meeting with 
Abbott in mid-December to facilitate registration. The 
company requested a postponement and the Thai FDA 
agreed to delay until Jan 4, 2007, but Abbott again failed 
to send a complete dossier within this deadline. Finally, 
the Thai FDA took the unprecedented step of proceeding 
with registration anyway, given the pressing need for 
this drug in Thailand.
Why did Abbott stall the registration process for its 
new drug? One industry analyst has suggested that “it 
may be legitimate for Abbott to want to build up the 
more proﬁ  table US market before expanding globally”.
6 
In 2006, sales exceeded US$1·1 billion, of which 
45% came from the USA
7 (a country with only 3% of 
the global HIV burden). One has to question how big a 
western market Abbott requires before the needs of the 
less developed world are considered.
A second issue aﬀ  ecting access is price. Abbott has 
set an annual price of $2200 per patient for lopinavir-
ritonavir in Thailand—more than six times the current 
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cost of ﬁ  rst-line antiretroviral therapy, and too expensive 
for a country where the average annual wage is $1600 a 
year. By contrast, production costs of lopinavir-ritonavir 
have been estimated by WHO to be as low as $338 per 
patient per year.
8 On April 10, 2007, Abbott announced 
a new lopinavir-ritonavir price of $1000 per patient per 
year for governments of more than 40 low and low-
middle income countries. However, the company has yet 
to specify which countries are able to beneﬁ  t from this 
price.
9
As a consequence of the much higher price that 
Thailand is obliged to pay, the drug is rationed. Currently 
around 90  000 people are receiving antiretroviral 
therapy in Thailand and an increasing number need 
to switch to second-line regimens. It is estimated that 
around 8000 people would currently beneﬁ  t  from 
lopinavir-ritonavir, but in 2006 the Thai Ministry of 
Public Health was only able to aﬀ  ord the drug for around 
600 people, leaving more than 90% of people currently 
in need of lopinavir-ritonavir without access.
To provide the best possible care for people with 
HIV/AIDS, the Thai government—and those of other 
developing countries—needs to be able to take action 
if a drug company refuses to make an essential drug 
available at an aﬀ  ordable price. The patent for lopinavir-
ritonavir will not expire in Thailand until 2016. Patients 
failing ﬁ  rst-line antiretroviral therapy in Thailand cannot 
wait 10 years to be able to access a generic version of 
a drug that has been in common use in the USA since 
1996. 
Abbott claims that by issuing a compulsory licence 
Thailand is “ignoring the patent system” but compulsory 
licensing is an integral part of national and international 
(World Trade Organization) intellectual property law;
10 
its use in Thailand has been advocated by the World 
Bank
11 and various UN agencies
12 as a way to respond 
to rising antiretroviral drug costs. WHO has conﬁ  rmed 
that Thailand’s actions fully comply with international 
law,
2 and this has been reiterated by statements from 
other governments;
13 even the US government—
which traditionally takes a strong stance in favour of 
intellectual property rights—respects the legal right of 
Thailand to issue compulsory licences.
2
By ignoring repeated requests to make its drug 
available and aﬀ  ordable in Thailand, Abbott left the 
Thai government with little other choice than to seek 
alternative sources of this medicine. The fact that 
Abbott is now withholding all other new medicines 
from Thailand demonstrates a total disregard for both 
public health in developing countries and the spirit and 
intent of the patent system it pretends to uphold. 
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